SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The stock is trending due to heightened speculation around impending Phase 3 results for its lead AML immunotherapy, GPS, with the CEO's recent remarks on "curative outcomes" fueling strong community belief in a positive data readout and potential buyout. This has intensified discussions of a significant short squeeze as institutional accumulation is noted and the stock approaches new highs.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid intense community speculation of an impending short squeeze, driven by perceived technical breakouts and widespread anticipation of strategic announcements or positive earnings from Chairman Ryan Cohen, with many noting its resilience in a volatile market.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

ANTX is trending due to a cluster of recent positive developments including a $40 million private placement, new strategic partnerships with GSK and DNDi, and an analyst upgrade, sparking intense community debate between aggressive bulls targeting significant price appreciation and bears pointing to past trial setbacks and potential dilution.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 trial data for its bladder cancer candidate, NDV-01, which reported a durable 76% complete response rate and reinforced plans for Phase 3 trials. The company's recently announced $160 million private placement to fund further development is also a key talking point, with the community actively discussing the drug's potential and the financing's implications for its future trajectory.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

Aureus Greenway Holdings is trending due to its announced merger with drone manufacturer Powerus, backed by Eric and Donald Trump Jr., signaling a significant pivot into the defense-drone sector amid rising military tech demand. Community discussion reflects strong enthusiasm for potential government contracts and short squeeze opportunities, while also acknowledging concerns around the stated merger valuation and recent share dilution.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is highly active as crude oil experiences significant volatility, with many traders anticipating a sharp downturn after recent geopolitical tensions led to price surges. The community is aggressively buying this inverse ETF, viewing current oil levels as overbought and primed for a major correction.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating Middle East tensions and surging oil prices fuel expectations for increased market volatility, with the community sharply divided between those buying dips as a market hedge and others anticipating a "VIX crush" or inherent decay in the leveraged ETF.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating Middle East tensions, particularly the Strait of Hormuz closure and production cuts by key oil producers, have sent crude prices soaring. Community discussion is highly polarized, with some anticipating further parabolic gains, while others foresee a sharp pullback as G7 nations consider a significant strategic oil reserve release and potential escort missions to reopen the strait.

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Calamp Corp.

Calamp Corp. is currently trending due to its Chapter 11 bankruptcy filing and plan to go private, which is expected to eliminate existing shareholder equity. Investors are actively discussing the impending delisting and the ultimate value of their holdings.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending after resolving its legal dispute with Novo Nordisk and announcing a partnership to offer FDA-approved GLP-1 weight-loss medications on its platform. This development has largely eliminated the previous bear thesis, fueling significant short-squeeze speculation and community discussion about the company's long-term potential as a digital health and wellness platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.read more...

Why Is Relmada Therapeutics Stock Soaring Monday?

Relmada Therapeutics shares rise on promising interim data from Phase 2 trial of NDV-01 for non-muscle invasive bladder cancer.read more...

<ul class="summary-bullets"><li>The company said that these interim results support advancement into the Phase 3 RESCUE registrational trial program to evaluate NDV-01.</li><li>Relmada also announced that it has entered into a securities purchase agreement for a private investment in public equity financing, with gross proceeds of $160 million expected.</li><li>The company stated that it intends to use the proceeds for working capital and general corporate purposes, including advancing the research and development of its product candidates.</li></ul>Relmada Therapeutics Inc. (RLMD) shares soared more than 66% in Monday’s pre-market trade before paring some of the gains after the company announced an update in the Phase 2 trial of its bladder cancer treatment.Relmada stated that NDV-01 demonstrated a durable 76% complete response (CR) rate at 12 months, with 95% CR rate at any time in high-risk non-muscle invasive bladder cancer (NMIBC).<a href="https://stocktwits.com/symbol/RLMD">Relmada Therapeutics shares</a> were up nearly 38% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Do These Findings Signify?</h2>Relmada stated that its Phase 2 trial findings of NVD-01 demonstrated a 12-month CR rate of 80% in the BCG-unresponsive population. The company stated that this is one of the most difficult-to-treat segments of NMIBC.“We continue to observe strong responses in patients with BCG-unresponsive disease, with no progression to muscle-invasive disease and no patients requiring radical cystectomy,” said Relmada’s Chief Medical Officer-Oncology, Raj S. Pruthi.The company said that these interim results support advancement into the Phase 3 RESCUE registrational trial program to evaluate NDV-01.<h2 class="st-heading-2">What Is NDV-01?</h2>NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce) being developed to treat non-muscle invasive bladder cancer. It is designed to retain the drugs in the bladder and release them gradually over a 10-day period.NDV-01 comes ready to use and can be administered in about five minutes without anesthesia or specialized equipment. It is protected by patents through 2038.The company highlighted three upcoming milestones of NDV-01. It expects clearance for its Investigational New Drug (IND) application and the initiation of its Phase 3 RESCUE Program by mid-2026. The initial 3-month results from its Phase 3 2L BCG-unresponsive study are expected by the end of the year.<h2 class="st-heading-2">Relmada Announces $160 Million Financing</h2>Relmada also announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing, expecting gross proceeds of $160 million.The company stated that it intends to use the proceeds for working capital and general corporate purposes, including advancing the research and development of its product candidates.<a href="https://stocktwits.com/symbol/RLMD">RLMD stock</a> is up 24% year-to-date and 1,987% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-ceasefire-discussions-irrelevant-us-israel-want-to-fragment-country/cZdVSRXRIIX">Iran Says Ceasefire Discussions 'Irrelevant', Warns US And Israel Want To Fragment The Country: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors

Relmada stated that the therapy showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer.

Equity

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders PR Newswire VANCOUVER, BC, Feb. 26, 2026...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Hold" from Analysts

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are covering the company, Marketbeat.com...

Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% - Here's Why

Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% - Should You Buy...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Rating of "Hold" by Analysts

Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) has been assigned an average rating of "Hold" from the five analysts that are presently covering the stock, MarketBeat reports. One...

Relmada Therapeutics (NASDAQ:RLMD) Upgraded by Leerink Partners to Outperform Rating

Leerink Partners upgraded Relmada Therapeutics from a "market perform" rating to an "outperform" rating and set a $8.00 price target on the stock in a report on Friday...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update

Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 980,736...

Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group

Jefferies Financial Group raised Relmada Therapeutics to a "strong-buy" rating in a report on Monday...

Iran / Geopolitical tensions

Fed speakers

Macro data

Earnings

What will be the primary market driver this week?

Stocktwits

Stocktwits Polls

Positive 12-month Phase 2 trial data for bladder cancer candidate NDV-01, showing a 76% complete response rate, is driving significant investor interest.

An oversubscribed $160 million private placement provides capital for advancing NDV-01 development, though some express dilution concerns.

High short interest and price movements are fueling speculation among traders that a short squeeze may trigger further upward momentum.

Despite some volatility, the stock is consolidating higher lows and showing strong pre-market and intraday gains, exciting momentum traders.

RLMD
Relmada Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RLMD News

RLMDRelmada Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RLMD News

RLMD
Relmada Therapeutics Inc